Papers by Antonella Prudenzano
Haematologica, 2000
Fludarabine has been recently reported as ineffective in mobilizing peripheral blood stem cells (... more Fludarabine has been recently reported as ineffective in mobilizing peripheral blood stem cells (PBSC) in acute myeloid leukemia (AML) patients. We report herein on 27 AML patients, 9 of them being eligible for peripheral blood stem cell transplantation (PBSCT). Eight of the 9 successfully mobilized after two courses of a fludarabine-containing regimen and the administration of CTX at a dose of 4 g/m 2 .
Haematologica, 2001
... Ferrata Storti Foundation Page 2. 1105 haematologica vol. ... Patrizio Mazza, Giulia Palazzo,... more ... Ferrata Storti Foundation Page 2. 1105 haematologica vol. ... Patrizio Mazza, Giulia Palazzo, Barbara Amurri, Giancarla Pricolo, Antonella Prudenzano, Loredana Stani Unità Operativa di Ematologia Azienda Ospedale SS Annunziata Strada per Martinafranca, Taranto, Italy ...
The coronavirus disease 2019 (COVID-19) pandemic is a worldwide medical challenge due to the scar... more The coronavirus disease 2019 (COVID-19) pandemic is a worldwide medical challenge due to the scarcity of proper information and remedial resources. The ability to efficiently avoid a further SARS-CoV-2 pandemic will, therefore, depend on understanding several factors which include host immunity, virus behavior, prevention measures, and new therapies. This is a multi-phase observatory study conducted in the SG Moscati Hospital of Taranto in Italy that was converted into COVID-19 Special Care Unit for SARS-Co-V2 risk management. Patients were admitted to the 118 Emergency Pre-Hospital and Emergency Department based on two diagnostic criteria, the nasopharyngeal swab assessed by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) and CT-scan image characterized by ground glass opacity. Patients were divided into four groups, positive-positive (ER-PP), negative-positive (ER-NP), negative-negative (ER-NN) and a group admitted to the ICU (ER-IC). A further control group was added whe...
Extramedullary Plasmacytoma (EM) disease is an aggressive presentation at diagnosis and relapse f... more Extramedullary Plasmacytoma (EM) disease is an aggressive presentation at diagnosis and relapse for multiple myeloma (MM) patients. EM plasmacytoma is divided into two groups: the first group comprises tumors that are extending directly from osteolytic bone lesions while the second results from plasmacytoma infiltration into soft tissues, with no relationship to the bone. Despite new therapies and monoclonal antibodies the survival for patients with EM plasmocytoma is poor. The involvement pleural is uncommon in Multiple Myeloma.
Blood
The major difficulty in the treatment of Jehovah’s Witnesses with haematological malignancies is ... more The major difficulty in the treatment of Jehovah’s Witnesses with haematological malignancies is the deny to the transfusion of blood products as support to chemo-radiotherapy; since the use of any form of bone marrow transplantation it is instead not precluded, this may be an alternative. From 1997 to July 2004 we treated 9 Jehovah’s Witnesses with de novo acute leukaemia without transfusions of blood products; in the same period 10 Jehovah’s Witnesses with various malignancies received high-dose therapy as conditioning to autologous PBSCT or allogeneic BMT. Acute leukaemia consisted of FAB-M3 4 patients (pts), FAB-M4 1 pt, FAB-L1 1 pt, FAB-L2 2 pts, FAB-L3 1 pt. Hb at diagnosis was 10.3g/dL mean (5.5–14.0 range), PLT at diagnosis were 40x10^3/μL mean (5–197 range). The mean age of pts was 26.2 years (2–49 range). The treatment consisted of protocols in use in our Institution at the time of diagnosis. The nadir of Hb was 5.3g/dL mean (1.3–8.3 range) and it was reached 10 days mean ...
Microorganisms
Background: A novel coronavirus (SARS-CoV-2)-induced pneumonia (COVID-19) emerged in December 201... more Background: A novel coronavirus (SARS-CoV-2)-induced pneumonia (COVID-19) emerged in December 2019 in China, spreading worldwide. The aim of the present investigation was to evaluate the immunological response and the clinical subset of peripheral lymphocyte subset alteration in COVID-19 infection. Methods: the study was conducted on four different clinical groups (n = 4; total n = 138). Each individual was assigned to different groups based on specific criteria evaluated at the admission such as fever, dyspnea, arterial blood gas analysis (ABG), oral-nasopharyngeal swab/RT-PCR, and thoracic CT-scan. Treatment was performed only after blood samples were collected from each patient (PP and PP) at day 1. The blood samples were analyzed and tested the same day (CBC and Flowcytometry). The positive–positive group (PP n = 45; F = 18/ M = 27; median age = 62.33), comprised individuals affected by COVID-19 who showed fever, dyspnea (ABG = pO2 < 60), confirmed positive by oral-nasopharyn...
Blood
Association between fludarabine (Fluda) and cytosine arabinoside (ARA-C) have shown in a variety ... more Association between fludarabine (Fluda) and cytosine arabinoside (ARA-C) have shown in a variety of single arm studies an effective antileukemic effect with acceptable toxicity in high risk myelodisplasias and acute myeloid leukemias in elderly patients. In order to increase the synergistic effect of fluda and ARA-C further association (i.e. anthracyclines) or different schedules of administration (i.e. continous infusion) have been performed but not compared. In order to asses if there is an advantage of an association or schedule compared to another we retrospectively analyzed results from two different fludarabine-based regimens administered as front-line therapy in patients with acute myeloid leukemias aged up to 60 years. A total of 42 patients were treated with fluda 25 mg/m2, ARA-C 1 gr/m2 and idarubicin 5 mg/m2 as single day administration for three days (FLAI) or fluda 20 mg/m2 and ARA-C 1,4 mg/m2 as continuous infusion for three days fluda and 4 days ARA-C (c.i.FLA). Total...
Uploads
Papers by Antonella Prudenzano